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Abstract How huntingtin (HTT) triggers neurotoxicity in Huntington’s disease (HD) remains
unclear. We report that HTT forms a transcription-coupled DNA repair (TCR) complex with RNA
polymerase II subunit A (POLR2A), ataxin-3, the DNA repair enzyme polynucleotide-kinase-3’-
phosphatase (PNKP), and cyclic AMP-response element-binding (CREB) protein (CBP). This complex
senses and facilitates DNA damage repair during transcriptional elongation, but its functional
integrity is impaired by mutant HTT. Abrogated PNKP activity results in persistent DNA break
accumulation, preferentially in actively transcribed genes, and aberrant activation of DNA damage-
response ataxia telangiectasia-mutated (ATM) signaling in HD transgenic mouse and cell models. A
concomitant decrease in Ataxin-3 activity facilitates CBP ubiquitination and degradation, adversely
impacting transcription and DNA repair. Increasing PNKP activity in mutant cells improves genome
integrity and cell survival. These findings suggest a potential molecular mechanism of how mutant
HTT activates DNA damage-response pro-degenerative pathways and impairs transcription,
triggering neurotoxicity and functional decline in HD.
DOI: https://doi.org/10.7554/eLife.42988.001
Introduction
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by a CAG
triplet repeat expansion in exon 1 of the HTT gene that is translated into polyglutamine (polyQ)
sequences in the huntingtin (HTT) protein which leads to progressive deterioration of cognitive and
motor functions (The Huntington’s Disease [MACDONALD, 1993; Ross and Tabrizi, 2011;
Vonsattel and DiFiglia, 1998]). The polyQ expansion in the mHTT protein leads to progressive
degeneration most overly affecting g-aminobutyric acid (GABA)-releasing striatal neurons and
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glutamatergic cortical neurons, although neuronal dysfunction and tissue atrophy in other brain
regions is also present (Vonsattel and DiFiglia, 1998; Ross and Tabrizi, 2011). Altered conforma-
tion of the mutant protein is reported to reduce normal function of the protein as well as facilitate
aberrant protein-protein interactions or subcellular localization, leading to neurotoxicity. Among the
numerous molecular interactions and signaling pathways implicated in HD pathomechanism, tran-
scriptional dysregulation (Jimenez-Sanchez et al., 2017; Ross and Tabrizi, 2011; Valor, 2015),
mitochondrial (mt) dysfunction (Shirendeb et al., 2011; Siddiqui et al., 2012), DNA strand break
accumulation, and atypical ataxia telangiectasia-mutated (ATM) pathway activation, involved in the
DNA damage response (Bertoni et al., 2011; Giuliano et al., 2003; Illuzzi et al., 2009; Xh et al.,
2014), have emerged as key players in HD-related neuronal dysfunction. Genetic or pharmacological
ablation of ATM activity to ameliorate the consequence of aberrant ATM activation decreased neu-
rotoxicity in HD animal models and HD induced pluripotent stem cells, respectively (Xh et al.,
2014), supporting the emerging view that inappropriate and chronic DNA damage-response (DDR)
pathway activation is a critical contributor to HD pathogenesis. Although, recent genome-wide asso-
ciation (GWA) studies and genetic data from other sources suggest that DNA damage and repair
pathways are central to the pathogenesis of HD and other diseases associated with CAG repeat
expansion (Bettencourt et al., 2016; Lee et al., 2015), the perplexing questions that remain to be
elucidated include how polyQ expansion induces DNA strand breaks, activates the DDR pathway,
and disrupts transcription. It is also unclear whether transcriptional dysregulation and atypical ATM
activation are mechanistically interconnected. We recently reported that the wild-type (wt) form of
the deubiquitinating enzyme ataxin-3 (wtATXN3) enhances the activity of polynucleotide kinase-3’-
phosphatase (PNKP), a bifunctional DNA repair enzyme with both 3’-phosphatase and 5’-kinase
activities that processes unligatable DNA ends to maintain genome integrity and promote neuronal
survival. In contrast, mutant ATXN3 (mATXN3) abrogates PNKP activity to induce DNA strand breaks
and activate the DDR-ATMfip53 pathway, as observed in spinocerebellar ataxia 3 (SCA3;
Chatterjee et al., 2015; Gao et al., 2015). Furthermore, we recently reported that PNKP plays a
eLife digest Our DNA encodes the instructions to make proteins, which then go on to perform
many crucial roles in the cell. Breakages and damage to DNA occur over time, and if uncorrected,
they can make the instructions illegible or incorrect. A build-up of damages can be harmful – for
example, DNA damage from excessive UV light exposure can cause skin cancer. Luckily, cells
contain DNA repair complexes, protein machines that surveil DNA and correct errors or breakages.
An accumulation of DNA breakages is thought to contribute to the development of Huntington’s
disease, a devastating and currently incurable condition where brain cells slowly die. The immediate
cause of Huntington’s disease is well known: Huntington’s patients have an abnormal, mutant
version of a protein called huntingtin. However, it is still unclear how the mutant huntingtin causes
the symptoms of the disease and participates in cell death.
Gao et al. carefully studied the proteins that huntingtin physically interacts with. The experiments
revealed that huntingtin is part of a newly identified DNA repair complex that fixes breakages in
DNA as the molecule is ‘read’ by the cell. The presence of the normal huntingtin protein promoted
DNA repair. However, when the healthy huntingtin was replaced with the mutant version found in
Huntington’s disease, the activity of the DNA repair complex was greatly reduced. This resulted in a
build-up of DNA errors, triggering a series of events that ultimately led to cell death. In addition, in
mice engineered to produce the mutant version of huntingtin, the accumulation of DNA damage
was particularly important in two brain regions that are severely damaged in patients with
Huntington’s disease.
There is currently no effective treatment for Huntington’s disease. However, understanding how
the mutant huntingtin damages brain cells may provide new targets for future therapies. More
broadly, several other brain disorders share similarities with Huntington’s disease, and it remains to
be seen whether the same mechanisms could be at work in all these conditions.
DOI: https://doi.org/10.7554/eLife.42988.002
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key role in transcription-coupled base excision repair (TC-BER) and transcription-coupled double
strand break repair (TC-DSBR) (Chakraborty et al., 2015; Chakraborty et al., 2016).
Here our data demonstrate that wtHTT is a part of a transcription-coupled DNA repair (TCR)
complex formed by RNA polymerase II subunit A (POLR2A), basic transcription factors, PNKP,
ATXN3, DNA ligase 3 (LIG 3), cyclic AMP response element-binding (CREB) protein (CBP, histone
acetyltransferase), and this complex identifies lesions in the template DNA strand and mediates their
repair during transcriptional elongation. The polyQ expansion in mHTT impairs PNKP and ATXN3
activities, disrupting the functional integrity of the TCR complex to adversely impact both transcrip-
tion and DNA repair. Low PNKP activity leads to persistent accumulation of DNA lesions, predomi-
nantly in actively transcribing genes, resulting in unusual activation of the ATM-dependent p53
signaling pathway. Increased PNKP activity in mutant cells improved cell survival by substantially
reducing DNA strand breaks and restricting ATMfip53 pathway activation. Likewise, low ATXN3
activity increases CBP ubiquitination and degradation thereby negatively influencing CREB-depen-
dent transcription. These findings provide important mechanistic insights that could explain how
mHTT may trigger neurotoxicity in HD.
Results
HTT is part of a TCR complex
Both wtHTT and mHTT interact with transcription factors and co-activators including CBP
(McCampbell et al., 2000; Nucifora et al., 2001; Steffan et al., 2000), TATA-binding protein (TBP;
Huang et al., 1998), p53 (Bae et al., 2005; Steffan et al., 2000), the general transcription factors
TFIID and TFIIF (Zhai et al., 2005), and specificity protein 1 (Sp1; Dunah et al., 2002). POLR2A also
interacts with HTT and is detected in nuclear inclusions in the HD brain (Huang et al., 1998;
Suhr et al., 2001). It is hypothesized that wtHTT, which shuttles into the nucleus, assists in the
assembly of transcription factor and co-activator complexes to regulate target gene expression, and
that polyQ expansion perturbs the functional integrity of these complexes (Kumar et al., 2014;
Luthi-Carter and Cha, 2003; Ross and Tabrizi, 2011). How mHTT disrupts the activities of specific
promoters and whether mHTT-mediated transcriptional dysregulation is linked to DNA damage
accumulation and aberrant DDR pathway activation remains unknown.
Given that HTT interacts with huntingtin-associated protein 1 (HAP-1; Li et al., 1995), while
ATXN3 interacts with HAP-1 (Takeshita et al., 2011) and PNKP (Chatterjee et al., 2015; Gao et al.,
2015), we asked whether ATXN3 and PNKP might interact with HTT to form a TCR complex and if
this is affected by polyQ expansion. We isolated nuclear protein extract (NE) and cytosolic protein
extract (CE) from SH-SY5Y cells and the fractions were analyzed by western blot (WB) to determine
purity of nuclear protein fractions (Figure 1A). We immunoprecipitated (IP’d) endogenous wtHTT
from the NE of SH-SY5Y cells, and WBs of the immunocomplexes (ICs) showed the presence of
HAP-1, ATXN3, CBP, TAFII 130 (TAF4), POLR2A, PNKP, and LIG 3 (Figure 1B and Figure 1—figure
supplement 1). Similarly, IP of endogenous ATXN3 from NEs revealed these proteins in the ATXN3-
IC (Figure 1C and Figure 1—figure supplement 2). Finally, IP of PNKP from NEs confirmed that
they were also present in the PNKP-IC (Figure 1D and Figure 1—figure supplement 3). To verify
the specificity of these interactions in vivo, we analyzed the ICs for the presence of apurinic-apyrimi-
dinic endonuclease 1 (APE1), another critical DNA base excision repair (BER) enzyme that works
independently of PNKP-mediated BER pathways (Wiederhold et al., 2004). APE1 was not detected
(Figure 1B to D), suggesting interaction specificity and selectivity. Finally, IP of POLR2A again
revealed these proteins in the IC (Figure 1E and Figure 1—figure supplement 4). For further confir-
mation, we IP’d Myc-tagged HTT from the NEs of PC12 cells expressing Myc-tagged FL-wtHTT-Q23
or FL-mHTT-Q148. WB confirmed the presence of ATXN3, PNKP, POLR2A, CBP, and LIG three but
not APE1 in the Myc-IC (Figure 1F and G, Figure 1—figure supplements 5 and 6), suggesting that
HTT, POLR2A, CBP, ATXN3, LIG 3, and PNKP form a multiprotein TCR complex. Proximity ligation
assays (PLAs) were then performed to verify interaction specificity (Gao et al., 2015). The reconstitu-
tion of fluorescence in neuronal cells (Figure 1H to M) and postmortem human brain sections (Fig-
ure 1—figure supplement 7) suggested substantial interaction among these proteins. Importantly,
the majority of the PLA signals was from the nuclei but substantial amount of signals were from the
periphery or cytoplasm. Immunostaining the cells with mitochondrial markers suggested that HTT
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Figure 1. HTT is a part of the TCR complex. (A) Nuclear extract (NE), and cytosolic extract (CE) were purified from human neuroblastoma SH-SY5Y cells
and the protein fractions were analyzed by western blots (WBs) to detect HTT, ATXN3, PNKP, and HAP1 levels in these sub-cellular fractions. GAPDH
and hnRNPC1/C2 were used as cytosolic and nuclear markers respectively. APE1 was used as a negative control in panels A to D. (B) Endogenous HTT
was immunoprecipitated (IP’d) from NEs of SH-SY5Y cells and immunocomplex (IC) were analyzed by western blot (WB) to examine the TCR proteins
Figure 1 continued on next page
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forms similar complexes in the mitochondria (data not shown). Importantly, about 60–70% of the
PLA signal was nuclear in control brain, while the complexes were predominantly in the perinuclei or
cytoplasm of HD brain sections (Figure 1—figure supplement 7). Since PNKP and HTT are present
in the mitochondria (Mandal et al., 2012; Orr et al., 2008), the extranuclear signals detected in the
control subjects are presumably from mitochondrial HTT-ATXN3-PNKP complexes. WB analysis of
subcellular protein fractions from neuronal cells show the presence of HTT, ATXN3 and PNKP in
mitochondria (data not shown). Moreover, co-staining the cells or brain sections with mitochondrial
markers suggested presence of HTT, ATXN3 and PNKP in mitochondria (data not shown). These
findings indicate that HTT may form a similar complex in mitochondria regulating mtDNA repair and
transcription.
The possible in vivo association of these proteins was further assessed by immunostaining HTT,
PNKP, and ATXN3 in postmortem brain tissue from patients with HD and control subjects. Confocal
microscopy revealed colocalization of HTT with PNKP and ATXN3 in HD and control brain
(Figure 2A & B; arrows). Colocalization of ATXN3 with PNKP was observed in both groups
(Figure 2C; arrows). Marked HTT/PNKP colocalization was also observed in brain sections from HD
knock-in (zQ175; Menalled et al., 2012) and WT control mouse brain tissue (data not shown).
The C-terminal catalytic domain of PNKP interacts with HTT
PNKP contains an N-terminal fork head-associated (FHA) domain, C-terminal fused 3’-phosphatase
(PHOS) domain, and 5’-kinase (KIN) domain. The PHOS domain hydrolyzes 3’-phosphate groups,
while the KIN domain promotes addition of a phosphate group to the 5’-OH at damaged sites for
error-free repair (Karimi-Busheri et al., 1999). To identify the specific PNKP domain(s) that interact
with HTT, full-length PNKP (FL-PNKP); the FHA, PHOS, and KIN domains; the FHA + PHOS domains;
or the PHOS + KIN domains were expressed as a FLAG-tagged peptide, as illustrated in Figure 3A.
We individually expressed these domains in SH-SY5Y cells (Figure 3B; upper panel) and isolated the
Figure 1 continued
(HAP-1, ATXN3, PNKP, POLR2A, LIG 3, CBP, and TAFII 130 (TAF4). (C) Endogenous ATXN3 was IP’d from NEs of SH-SY5Y cells and IC was subjected to
WB to detect associated TCR complex components with respective antibodies. (D) Endogenous PNKP was IP’d from NEs of SH-SY5Y cells and IC was
analyzed by WB to examine associated TCR components. (E) Endogenous POLR2A was IP’d from NEs of SH-SY5Y cells and IC was analyzed by WB to
detect associated TCR proteins. (F) NEs was isolated from PC12 cells ectopically expressing a Myc-tagged full-length normal wild type HTT (FL-wtHTT-
Q23) for assessing the possible interaction of HTT with POLR2A and associated TCR proteins. Exogenous Myc-wtHTT-Q23 was IP’d with an anti-Myc
antibody, and the Myc immunocomplex was subjected to WBs with respective antibodies. APE1 was used as a negative control in panels F and G. (G)
NEs was isolated from PC12 cells ectopically expressing a Myc-tagged full-length mutant HTT (FL-mHTT-Q148). Exogenous Myc-wtHTT-Q148 was IP’d
with an anti-Myc antibody, and the Myc immunocomplex was subjected to WBs with respective antibodies. Proximity Ligation Assay (PLA) in SH-SY5Y
cells to examine the protein-protein interaction using the following antibody pairs. Red fluorescence indicates positive PLA signals for protein-protein
interactions. Nuclei were stained with DAPI. (H) ATXN3 (rabbit: Rb) and IgG (mouse: mo) or PNKP (mouse: mo) antibodies. (I) ATXN3 (rabbit: Rb) with
IgG (mouse: mo) or HAP-1 (mouse: mo) antibodies. (J) HAP-1 (rabbit: Rb) and IgG (mouse: mo) or HTT (mouse: mo) antibodies. (K) HTT (mouse: mo)
with IgG (rabbit: Rb) or ATXN3 (rabbit: Rb) antibodies. (L) HTT (mouse: mo) with IgG (rabbit: Rb) or PNKP (rabbit: Rb) antibodies, and. (M) POLR2A
(mouse: mo) with IgG (rabbit: Rb) or HTT (rabbit: Rb) antibodies.
DOI: https://doi.org/10.7554/eLife.42988.003
The following figure supplements are available for figure 1:
Figure supplement 1. Huntingtin is a part of the transcription-coupled DNA repair (TCR) complex.
DOI: https://doi.org/10.7554/eLife.42988.004
Figure supplement 2. ATXN3 is present in the HTT-TCR complex.
DOI: https://doi.org/10.7554/eLife.42988.005
Figure supplement 3. DNA strand break repair enzyme PNKP is present in the TCR complex.
DOI: https://doi.org/10.7554/eLife.42988.006
Figure supplement 4. RNA polymerase large subunit (POLR2A) is present in the HTT-TCR complex.
DOI: https://doi.org/10.7554/eLife.42988.007
Figure supplement 5. Wild-type normal HTT is a part of the multiprotein TCR complex in vitro.
DOI: https://doi.org/10.7554/eLife.42988.008
Figure supplement 6. Mutant HTT is a part of the multiprotein TCR complex in vitro.
DOI: https://doi.org/10.7554/eLife.42988.009
Figure supplement 7. HTT is a component of the TCR complex in vivo.
DOI: https://doi.org/10.7554/eLife.42988.010
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Figure 2. HTT colocalizes with PNKP and ATXN3 in postmortem human brain sections. (A) Normal and HD postmortem brain (mHTT-Q94) sections
were analyzed by double immunolabeling with antibodies against HTT (green) and PNKP (red) to assess their in vivo colocalization and possible
interactions (representative colocalization of HTT and PNKP are shown by arrows). For panels A and B, merge of red and green fluorescence appears as
yellow/orange, and nuclei were stained with DAPI (blue). (B) Normal and HD brain (mHTT-Q82; early onset HD patients, disease grade 4/4, manifesting
Figure 2 continued on next page
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NEs. IPs of these domains with a FLAG antibody and subsequent WB analysis of the IC showed the
presence of HTT in the FLAG-(FL-PNKP)-IC and FLAG-(PHOS + KIN)-IC (Figure 3B; Lower panel,
lanes 1 and 6, arrow). HTT was not detected in FLAG-ICs when the individual FHA, PHOS, or KIN
domains were IP’d (Figure 3B; lanes 2–5, arrow). This suggests that the C-terminal catalytic domain
of PNKP interacts with HTT, but the individual FHA, PHOS, and KIN domains are not sufficient. We
separately expressed the PNKP domains in cells, isolated the NEs, and IP’d endogenous HTT. WBs
revealed the presence of full-length and PHOS + KIN domains in the HTT-IC (Figure 3C; Lower
panel, lanes 1 and 6). When we expressed the PNKP domains in PC12 cells expressing Myc-wtHTT-
Q23 or Myc-mHTT-Q148 (Figure 3D & E; upper panels), IP of the Myc-HTT and WB revealed the
full-length protein or PHOS + KIN domain (Figure 3D & E, Lower panels, lanes 1 and 6). These data
suggest that both wtHTT and mHTT interact with the C-terminal catalytic domain of PNKP.
N-terminal-truncated HTT fragments interact with the catalytic domain
of PNKP
The N-terminal-truncated fragment of mHTT (NT-mHTT) containing the polyQ expansion is encoded
by exon 1 of the HTT gene. Transgenic mice expressing exon one or a truncated fragment extending
beyond the first exon (N171) with NT-mHTT recapitulate HD-like neurological and behavioral abnor-
malities (Mangiarini et al., 1996; Schilling et al., 1999). To test whether this fragment interacts with
PNKP, we expressed NT-wtHTT-Q23 or NT-mHTT-Q97 (1–586 base pairs) as a GFP-tagged peptide
in SH-SY5Y cells (Figure 4A; upper panel), isolated the NEs, and IP’d the GFP-NT-HTT fusion pep-
tide with a GFP antibody. WBs showed the presence of PNKP, ATXN3, and HTT in the GFP-IC
(Figure 4A; lower panel, lanes 4 and 6). We next IP’d this fragment from PC12 cells expressing Myc-
NT-wtHTT-Q23 or NT-mHTT-Q148 and found ATXN3, PNKP, POLR2A, CBP, and LIG three in the
Myc-IC. Importantly, APE1 was not detected in the IC, again suggesting interaction specificity
(Figure 4B). To identify which PNKP domain interacts with NT-HTT, we expressed various domains
as FLAG-tagged peptides in SH-SY5Y cells expressing either Myc-NT-HTT-Q23 or Myc-NT-HTT-Q97
(Figure 4C & D; upper panels) and IP’d Myc-tagged fragments from the NEs. WBs revealed FL-
PNKP and PNKP-(PHOS + KIN) domains in the Myc immunocomplex (Figure 4C & D; lanes 1 and 6),
suggesting that the N-terminal fragment of HTT interacts with the C-terminal catalytic domain of
PNKP. However, from the WB analyses we could not establish whether the interaction of the mutant
HTT fragment (NT-mHTT) with PNKP-(PHOS + KIN) domain is stronger than the interaction with the
N-terminal fragment of WT HTT (NT-wtHTT; Figure 4C & D; lanes 6). The PNKP-(FHA + PHOS)
domain also showed a relatively weaker interaction with the N-terminal fragment of HTT (Figure 4C
& D; lanes 5) indicating that the FHA-PHOS domain of PNKP alone interacts with the N-terminal
fragment of HTT.
To further assess these possible interactions, we performed bi-molecular fluorescence comple-
mentation (BiFC) assays as we previously reported (Gao et al., 2015). We cloned either the full-
length or C-terminal catalytic domain of PNKP at the N-terminus of cyan fluorescent protein (CFP)
into plasmid pBiFC-VN173 to construct plasmids pVN-PNKP and pVN-(PHOS +KIN), respectively.
We also cloned the N-terminal fragment of wtHTT and mHTT cDNA (encoding 23 and 97 gluta-
mines, respectively) at the C-terminus of CFP in plasmid pBiFC-VC155 to construct pVC-NT-HTT-
Q23 and pVC-NT-HTT-Q97, respectively (detailed descriptions of these plasmids are provided in the
STAR Methods). Cotransfection of plasmid pVN-PNKP with the parent plasmid pBIFC-VC155 did not
reconstitute fluorescence (Figure 4E; Panel 1), whereas cotransfection of pVN-PNKP with either
pVC-NT-HTT-Q23 or pVC-NT-HTT-Q97 did (Figure 4E; Panels 2 and 3). Similarly, cotransfection of
pVN-(PHOS +KIN) with pBIFC-VC155 did not produce fluorescence (Figure 4E; Panel 4), whereas
cotransfection of pVN-(PHOS +KIN) with either pVC-NT-HTT-Q23 or pVC-NT-HTT-Q97 robustly
Figure 2 continued
severe phenotype) sections analyzed by double immunolabeling with antibodies against HTT (green) and ATXN3 (red) to assess their in vivo
colocalization and possible interaction (arrows). (C) Normal and HD brain (mHTT-Q94; early onset HD patients, disease grade 4/4, manifesting severe
phenotype) sections were analyzed by double immunolabeling with antibodies against ATXN3 (green) and PNKP (red) to assess their in vivo
colocalization and possible interaction (arrows).
DOI: https://doi.org/10.7554/eLife.42988.011
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Figure 3. HTT interacts with the C-terminal catalytic domain of PNKP. (A) Schematic illustrating various functional domains of PNKP expressed as
FLAG-tagged peptides: (1) full-length PNKP containing N-terminal fork-head-associated (FHA) domain, central phosphatase (PHOS) and C-terminal
kinase (KIN) domains; (2) FHA domain (1–130 amino acids); (3) PHOS domain (131–337 amino acids); (4) KIN domain (338–521 amino acids); (5) FHA and
PHOS domains (1–137 amino acids); and (6) PHOS and KIN domains (131–521 amino acids). (B) Plasmids encoding full-length PNKP (FL-PNKP) or
Figure 3 continued on next page
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reconstituted fluorescence (Figure 4E, Panels 5 and 6). Although these data suggest that the N-ter-
minal of mHTT interacts with PNKP, these experiments do not inform the relative strengths of inter-
action between these peptides. Nonetheless, the IP and BIFC studies suggest that the truncated-N-
terminal fragments of both WT and mHTT interact with the C-terminal catalytic domain of PNKP.
The interaction of these peptides with the PHOS-KIN domain of PNKP is relatively stronger than
with the PHOS domain alone. However, more rigorous structural and biophysical measurements
using purified proteins/peptides will be required to understand the true nature of these protein-pro-
tein interactions, the relative binding efficacies and to identify the direct interacting partners in this
complex. Moreover, since the HTT-TCR complex is not fully characterized, the presence of additional
unidentified components of the complex could significantly alter these interactions in vivo.
mHTT abrogates PNKP activity to induce DNA damage and trigger
DDR signaling
Given that PNKP interacts with mHTT, we measured the 3’-phosphatase activity of PNKP in induced
pluripotent stem cells (iPSCs) differentiated to neurons enriched for medium striatal neuronal popu-
lations from HD and unaffected control subjects using a modification of Telezhkin et al. (2016). HD
iPSC-derived neurons (mHTT-109Qs) were compared to control neurons (wtHTT-33Q; HD iPSC
HD iPSC Consortium, 2017) and activity was found to be 70–80% lower in the NE of HD neurons,
while PNKP protein levels did not change (representative experiment, Figure 5A to C). Similar differ-
ences were found for neurons with adult onset alleles (Q50 and Q53) compared to controls (Q18
and Q28). In these comparisons there was substantially reduced (70% to 80%) PNKP activity in HD
neurons (Q50 and Q53) compared with control neurons (Q18 or Q28) (Figure 5—figure supplement
1), supporting an impairment in human neurons in the presence of mHTT.
We next measured PNKP activity in PC12 cells expressing exogenous full-length wtHTT (FL-
wtHTT-Q23) and full-length mHTT (FL-mHTT-Q148) (Igarashi et al., 2003; Tanaka et al., 2006). We
found that it was about 30–40% higher in the NE of PC12 cells expressing wtHTT, and about 70%
lower in the NE of PC12 cells expressing FL-mHTT-Q148 compared to control cells, while PNKP pro-
tein levels did not change (Figure 5—figure supplement 2A to C). These data suggest that wtHTT
and mHTT stimulate and abrogate PNKP activity, respectively. Since wtHTT interacts with and stimu-
lates PNKP activity, we examined the extent to which HTT depletion alters PNKP activity. We found
that in HTT-depleted cells, PNKP activity was reduced by >70% (Figure 5—figure supplement 2D
to G), suggesting that wtHTT plays key roles in stimulating PNKP activity, maintaining the functional
integrity of the TCR complex, and repairing DNA damage. PNKP activity was 80–90% decreased in
the striatum (STR) and cortex (CTX), and marginally (5%) decreased in the cerebellum (CRBL) of male
heterozygous asymptomatic zQ175 mice at 7 weeks, whereas PNKP protein levels were not different
from WT (Figure 5D to F). An identical trend was observed in female littermates (data not shown).
Because the N-terminal of mHTT interacts with PNKP, we investigated whether N-terminal trun-
cated fragment of mHTT interferes with PNKP activity in PC12 cells or N171-82Q mice
(Schilling et al., 1999; Tanaka et al., 2006). PNKP activity was ~30% higher in PC12 cells expressing
Figure 3 continued
various PNKP domains were separately transfected into SH-SY5Y cells (lanes 1 to 6) and NEs isolated 48 hr post-transfection. Lanes 1 to 6 in the WB
(upper panel) shows the pull-down of full-length PNKP (FL-PNKP) and various PNKP domains that were IP’d with an anti-FLAG Ab. The WB in the lower
panel shows the presence of endogenous HTT (arrow) in the FLAG-IC. M: protein molecular weight marker. (C) Plasmids encoding full-length PNKP (FL-
PNKP) and various PNKP domains were separately transfected into SH-SY5Y cells (lanes 1 to 6), NEs isolated, and HTT was IP’d with an anti-HTT
antibody. The pull-down of endogenous HTT is shown in the upper panel (arrow). The HTT-IC was analyzed by WB (lower panel) to detect FL-PNKP or
various PNKP domains with an anti-FLAG Ab (arrows). (D) Plasmids encoding FLAG-tagged full-length PNKP (FL-PNKP) or various PNKP domains were
transfected separately into PC12 cells expressing full-length Myc-tagged normal HTT encoding 23Qs (Myc-FL-wtHTT-Q23) (lanes 1 to 6), NEs were
isolated, and Myc-HTT IP’d with Myc tag antibody. Upper panel is the WB showing the IP of HTT with an anti-Myc tag antibody. The Myc-IC was
analyzed by WB to assess interaction of various PNKP domains with HTT with an anti-FLAG antibody (lower panel, arrows). (E) Plasmids encoding the
full-length PNKP (FL-PNKP) or various PNKP domains were transfected into PC12 cells expressing Myc-tagged full-length mutant HTT encoding 148Qs
(Myc-FL-mHTT-Q148) (lanes 1 to 6), NEs isolated, and Myc-tagged HTT was IP’d with an anti-Myc-tag antibody. Upper panel is the WB showing IP of
Myc-HTT with anti-Myc tag antibody. Interactions of FL-PNKP or various PNKP domains with FL-HTT were analyzed by WB with an anti-FLAG antibody
(lower panel, arrows).
DOI: https://doi.org/10.7554/eLife.42988.012
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Figure 4. The N-terminus of HTT interacts with the C-terminal catalytic domain of PNKP. (A) Schematic showing GFP-tagged N-terminal fragment of
wild-type normal HTT encoding 23Qs or mutant HTT encoding 97Qs (NT-wtHTT-Q23 and NT-mHTT-Q97 plasmid vectors respectively; upper panel).
SH-SY5Y cells were transfected with NT-wtHTT-Q23 or NT-mHTT-Q97, NEs isolated, fusion peptides IP’d from NE with an anti-GFP antibody, and WBs
performed with respective antibodies to detect endogenous PNKP, ATXN3, or HTT in the GFP-IC (lower panel). (B) NEs from PC12 cells expressing
Figure 4 continued on next page
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NT-wtHTT-Q23 and >80% lower in cells expressing NT-mHTT-Q148 (Figure 5—figure supplement
3A & B). Similar to full-length HTT, PNKP activity was decreased in SH-SY5Y cells expressing NT-
mHTT with variable glutamine expansions (Figure 5—figure supplement 3C & D). Moreover, PNKP
activity was >80% decreased in the STR and CTX of N171-82Q brain compared to control (Fig-
ure 5—figure supplement 3E & F). To test if mHTT specifically blocks PNKP activity rather than
interfering with DNA repair per se, we examined how it modulated the repair of two nicked DNA
duplexes: one without a 3’-phosphate end that requires DNA polymerase and ligase activities but
not PNKP activity for repair, and another duplex with a 3’-phosphate end that requires PNKP and
DNA polymerase and ligase activities for complete repair. We observed that NEs from cells express-
ing mHTT or from zQ175 mouse brain did not hamper repair of the duplex that required DNA poly-
merase and ligase activities but did not require PNKP activity. In contrast, NEs from these cells and
mice did abrogate repair of the duplex that requires PNKP (Figure 5G to J), suggesting that mHTT
specifically blocks PNKP activity but does not interfere with the activities of other repair enzymes in
the TCR complex. In response to DNA strand break accumulations, ATM is activated by phosphory-
lation which phosphorylates p53, which in turn activates pro-apoptotic gene transcription
(Chipuk et al., 2004; Nakano and Vousden, 2001; Oda et al., 2000). Consistently, we found
chronic activation of the DDR-ATM-p53 pathway in HD neurons Figure 5—figure supplement 4A &
B) and in zQ175 CTX (Figure 5—figure supplement 4C & D) compared with respective controls.
mHTT expression has been shown to activate p53 in HD, whereas deleting p53 in the HD transgenic
brain rescues behavioral abnormalities (Bae et al., 2005). Consistently, markedly increased mRNA
expression of p53 target genes (e.g., Bcl2L11, Pmaip1, Bid, Pidd1 and Apaf1) were observed in the
STR but not in CRBL of zQ175 mice compared to controls (Figure 5—figure supplement 4E & F).
We next expressed the N-terminal truncated fragment of mHTT encoding Q97 (NT-mHTT-Q97)
in SH-SY5Y cells overexpressing PNKP and carried out a comet assay (Olive and Bana´th, 2006).
Analysis of mutant cells showed more strand breaks, which were substantially rescued after PNKP
overexpression (Figure 5—figure supplement 5A to C), suggesting that mHTT-mediated ablation
of PNKP activity contributes to increased DNA strand breaks. Consistently, we noted activation of
ATM-p53 signaling in cells expressing NT-mHTT-Q97 (Figure 5—figure supplement 5D & E), and
PNKP overexpression reduced mHTT-mediated DDR-ATM pathway activation (Figure 5—figure
supplement 5F). PC12 cells expressing the full-length mHTT encoding 148Qs (FL-mHTT-Q148)
showed increased caspase-3 activity and PNKP overexpression reduced caspase-3 activation Fig-
ure 5—figure supplement 5G). Consistently, PC12 cells expressing FL-mHTT-Q148 also showed
higher cell toxicity and PNKP overexpression significantly rescued cell toxicity (Figure 5—figure sup-
plement 5H & I). Collectively, these results suggest that mHTT-mediated activation of the ATM-p53
pathway and associated cell toxicity is at least partially due to PNKP inactivation by mHTT.
mHTT preferentially induces DNA breaks in the transcriptionally active
genome
Emerging evidence suggests that the TCR complex plays a pivotal role in editing strand breaks in
actively transcribing template DNA to maintain genome integrity and cell survival, and its
Figure 4 continued
Myc-tagged N-terminal fragment of wild-type normal HTT encoding 23Qs or mutant HTT encoding 148Qs (NT-wtHTT-Q23 or NT-mHTT-Q148,
respectively) were isolated and the Myc-HTT was IP’d with an anti-Myc tag Ab and Myc-IC was analyzed by WBs to detect various TCR complex
components with respective antibodies. (C) Plasmids encoding full-length PNKP (FL-PNKP) or various PNKP domains (lanes 1 to 6) were separately
transfected into SH-SY5Y cells expressing the N-terminal fragment of HTT encoding 23Qs (Myc-NT-wtHTT-Q23), NEs were isolated and the NT-HTT
was IP’d with an anti-Myc tag Ab. The upper panel shows pull down of Myc-NT-HTT-Q23. The Myc-IC was analyzed by WBs with an anti-FLAG Ab to
detect FL-PNKP or PNKP domains (lower panel; arrows). (D) Plasmids encoding full-length PNKP (FL-PNKP) or various domains (lanes 1 to 6) were
separately transfected into SH-SY5Y cells expressing the N-terminal fragment of mutant HTT encoding 97Qs (Myc-mHTT-Q97) and NEs were isolated
and the Myc-NT-HTT-Q97 was IP’d with an anti-Myc tag Ab and the Myc-IC was analyzed by WBs to detect FL-PNKP or PNKP domains (lower panel;
arrows). (E) BiFC assay of SH-SY5Y cells cotransfected with plasmids: Panel 1) pVN173-PNKP and pVC-BIFC-155, Panel 2) pVN-PNKP and pVC-NT-
wtHTT-Q23, Panel 3) pVN-PNKP and pVC-NT-mHTT-Q97, Panel 4) pVN (PHOS + KIN) and pVC-BIFC-155, Panel 5) pVN-(PHOS + KIN) and pVC-NT-
wtHTT-Q23, and panel 6) pVN-(PHOS + KIN) and pVC-NT-mHTT-Q97. Reconstitution of fluorescence was monitored via fluorescence microscopy.
Nuclei were stained with DAPI (blue).
DOI: https://doi.org/10.7554/eLife.42988.013
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Figure 5. mHTT abrogates PNKP activity in vitro and in vivo. (A) The 3’-phosphatase activities of PNKP in the NE (250 ng each) of control (lanes 1 and 2,
differentiation replicates of Q33 iPSCs), and HD neurons (lanes 3 and 4, differentiation replicates of Q109 iPSCs) were determined by amount of
phosphate release from the DNA substrate (arrows). No protein extract was added to the substrate in lane 5 (NP), and purified PNKP (25 fmol) was
added as a positive control (lane 6). (B) Relative 3’-phosphatase activities (in terms of % product) of PNKP in control (Q33) and HD (Q109) neurons. Data
Figure 5 continued on next page
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inactivation leads to preferential accumulation of DNA breaks in the transcriptionally active genome
(Chakraborty et al., 2015; Chakraborty et al., 2016; Hanawalt and Spivak, 2008). Since mHTT
abrogates the activity of PNKP, a key component of the TCR complex (Chakraborty et al., 2016),
we compared the associations of HTT and TCR proteins with transcriptionally active versus inactive
genomes and asked whether the former accumulates more strand breaks in the HD brain. Chromatin
immunoprecipitation (ChIP) revealed significantly higher HTT occupancy on actively transcribing
genes in the brain (e.g., neuronal differentiation factor 1 and 2 [Neurod1 and Neurod2], neurogenic
basic-helix-loop-helix protein neurogenin 1 [Neurog1], tubulin beta three class III [Tubb3], neuron-
specific enolase 2 [Eno2g ], and DNA polymerase beta [Pol b]) over genes that are not transcribed in
the brain but actively transcribed in skeletal or cardiac muscle (e.g., myogenic differentiation factor 1
[Myod1]; myogenic factor 4; myogenin [Myog]; and myosin heavy chain 2, 4, 6, or 7 [Myh2, Myh4,
Myh6, or Myh7]; (Figure 6A & B). Increased association between HTT with the transcriptionally
active genome and mHTT-mediated abrogation of PNKP activity indicate that the wtHTT-TCR com-
plex repairs lesions during transcriptional elongation, but polyQ expansion might impair the TCR
and facilitate DNA damage accumulation. To test this theory, we performed Long-amplicon quanti-
tative polymerase chain reaction (LA-qPCR) analysis, a versatile technique to measure nuclear and
mitochondrial DNA damage (Gao et al., 2015; Santos et al., 2006) to assess DNA strand breakage
in actively transcribing and non-transcribing genes in the transgenic mouse cortex (CTX). The results
revealed 60–70% lower PCR-amplification of actively transcribing genes in asymptomatic (seven wks)
zQ175 mouse CTX compared to age-matched WT controls (Figure 6C & D). In contrast, the amplifi-
cation efficacy for non-transcribing genes in the zQ175 CTX was only marginally (10–15%) reduced
(Figure 6E & F), indicating less DNA damage accumulation. Consistent with the levels of PNKP
activities observed in the striatum (STR) and cerebellum (CRBL), the LA-qPCR analysis revealed
Figure 5 continued
represent mean ± SD, *p<0.001 when compared with control. The quantification was measured by taking into account two biological replicates and
three technical replicates. (C) NEs from control (Q33) and HD neurons (Q109) were analyzed by WB to determine PNKP protein levels (upper panel);
HDAC2 was used as a loading control (lower panel). (D) PNKP activities in the NEs from the striatum (STR), cortex (CTX) and cerebellum (CRBL) of 7
weeks old WT control and zQ175 transgenic mice (n = 5; STR or CTX or CRBL were pooled from five littermate mice); no protein was added to the
substrate in lane 1 (NP), and purified PNKP was added as a positive control (lane 8). (E) Relative PNKP activities (in terms of % product) in the STR, CTX,
and CRBL of 7 weeks old zQ175 transgenic (n = 5) and age-matched control (n = 5) mice. Five biological replicates and three technical replicates were
used in this study. Data represent mean ± SD, *p<0.001 when compared with control. (F) NEs from the STR, CTX, and CRBL of zQ175 (n = 5) and age-
matched wild type control (n = 5) mice were analyzed by WB to determine PNKP levels (upper panel); b-tubulin was used as a loading control (lower
panel). (G) mHTT specifically abrogates PNKP activity without interfering with DNA polymerase or ligase activities. Total DNA repair was assessed with
NE (2.5 mg) from control (Q33) and HD (Q109) neurons added to two nicked DNA duplexes (upper panel): one with 3’-phosphate ends that require
PNKP activity (lanes 2 and 3, lower panel), and the other with clean 3’-OH termini that do not require PNKP activity but need DNA polymerase and
ligase activities (lanes 4 and 5, lower panel) for effective repair. The 51-mer DNA band (arrow) represents repaired DNA duplexes in G and I. (H)
Relative PNKP and PNKP-independent DNA repair efficiencies in HD (Q109) and control (Q33) primary neurons. NS denotes not significant difference in
H and J. Two biological replicates and three technical replicates were used in this study. Data represent mean ± SD. (I) NEs from zQ175 transgenic
(n = 5) and control (n = 5) mice CTX and STR were added to nicked DNA substrates as described above, and total DNA repair was assessed. (J) PNKP-
dependent or -independent repair of the DNA duplexes by NEs from control and zQ175 transgenic mouse brain tissue. Data represent mean ± SD,
*p<0.001 for E, H, and J. Three biological replicates and three technical replicates were used in this assay.
DOI: https://doi.org/10.7554/eLife.42988.014
The following source data and figure supplements are available for figure 5:
Source data 1. Huntinton’s disease models.
DOI: https://doi.org/10.7554/eLife.42988.020
Figure supplement 1. Endogenous level of mHTT is sufficient to deplete nuclear PNKP activity in iPSC-derived HD primary striatal neurons.
DOI: https://doi.org/10.7554/eLife.42988.015
Figure supplement 2. mHTT-mediated inactivation of the TCR complex abrogates PNKP activity.
DOI: https://doi.org/10.7554/eLife.42988.016
Figure supplement 3. Expression of the N-terminus of mHTT abrogates PNKP activity.
DOI: https://doi.org/10.7554/eLife.42988.017
Figure supplement 4. mHTT triggers DNA damage response (DDR)-ATM signaling.
DOI: https://doi.org/10.7554/eLife.42988.018
Figure supplement 5. PNKP overexpression in mutant cells rescues cell toxicity.
DOI: https://doi.org/10.7554/eLife.42988.019
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Figure 6. mHTT preferentially induces DNA damage/strand breaks in the transcriptionally active genome. (A) Tissue from CTX and STR of 5 WT mouse
brain (7 weeks old) was pooled and total RNA was isolated and expression levels of various genes were measured using qRT-PCR analysis. Left panel
shows amplified product of transcribing genes and the right panel for non-transcribing genes. (B) ChIP analysis showing relative occupancy of wtHTT on
the actively transcribing (blue) vs. transcriptionally inactive (red) genome loci in 7 weeks old WT mouse STR. Three biological replicates and three
Figure 6 continued on next page
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substantial DNA damage accumulation in STR but negligible DNA damage accumulations in the
CRBL (Figure 6—figure supplement 1). Moreover, immunostaining of the HD patients’ brain and
HD transgenic mouse brain sections with anti-phospho-53BP1 antibody, a DNA damage marker,
showed increased presence of DNA damage as compared to control (Figure 6—figure supplement
2). Consistently, preferential accumulation of DNA strand breaks was observed in iPSC-derived HD
primary neurons (Q50 and Q53) than controls (Q18 and Q28) (Figure 6—figure supplement 3).
Increased DNA break accumulation was also observed in actively transcribing genes vs. non-tran-
scribing genes in the N171-82Q transgenic CTX than the age-matched controls Figure 6—figure
supplement 4). These data support our hypothesis that the HTT-TCR complex repairs strand breaks
during transcription, and that this function is impaired by polyQ expansion, resulting in persistent
strand break accumulation predominantly affecting actively transcribing genes in HD.
HTT facilitates CBP degradation by inactivating ATXN3
Given that the deubiquitinase ATXN3 is present in the TCR complex, interacts with mHTT, and is
sequestered in polyQ aggregates in HD brain, we postulated that compromised ATXN3 activity
might increase ubiquitination and decrease levels of TCR components, adversely impacting complex
functionality and transcription. To explore this possibility, we examined whether mHTT stimulates
ubiquitination and degradation of specific TCR complex proteins. WB analyses of NEs from HD and
control iPSC-derived primary neurons revealed a significant decrease in soluble CBP protein levels in
HD neurons, whereas ATXN3, PNKP, POLR2A, and CREB levels were not affected (Figure 7A & B).
Quantitative reverse transcription PCR analyses did not show a significant change in CBP mRNA lev-
els upon mHTT expression (data not shown), suggesting that mHTT does not interfere with the
expression of CBP in HD. This finding indicates that CBP might be degraded more in HD. However,
an alternative possibility is that CBP becomes insoluble when post-translationally modified. Substan-
tially reduced levels of CBP was also observed in the soluble fraction of proteins from cells express-
ing exogenous mHTT (data not shown). To determine whether abrogating ATXN3 activity causes
reduced CBP levels, we measured TCR protein levels in ATXN3-depleted cells. Similar to HD iPSC-
derived primary neurons, markedly lower CBP levels were observed in the soluble protein extract
from the ATXN3-depleted cells (Figure 7C & D). Consistent with a previous report (Cong et al.,
2005; Jiang et al., 2003), CBP levels were dramatically (~80%) reduced in the zQ175 CTX but only
marginally (~20%) decreased in the CRBL (Figure 7E & F). To test whether ATXN3 interacts with
Figure 6 continued
technical replicates were used in this assay. Data represent mean ± SD. (C) Genomic DNA was isolated from the CTX of asymptomatic (7 weeks old)
zQ175 transgenic (CTX from five transgenic mice were pooled) and age-matched WT control (CTX from 5 WT control mice were pooled) mice. Various
transcriptionally active gene loci (Neurod1, Neurod2, Neurog1, Tubb3, Eno2g , and Pol b) were PCR-amplified from the genomic DNA and analyzed on
agarose gels; L: long amplicon (6 to 12 kb product), S: short amplicon (200–300 bp). (D) Relative PCR amplification efficacies of various actively
transcribing gene loci in 7 weeks old WT control and zQ175 mouse brains (CTX). Data represent mean ± SD, *p<0.001. Five biological replicates each
with three technical replicates were used in this assay. (E) PCR amplification of genomic DNA isolated from the CTX of asymptomatic (7 weeks) zQ175
and WT control mice and various loci that are transcriptionally inactive in brain (Myod1, Myog, Myh2, Myh4, Myh6, and Myh7) were PCR amplified. PCR
products from WT control (lanes 1–3) and zQ175 mice (lanes 4 to 6) were analyzed on agarose gels. L: long amplicon (6 to 12 kb product), S: short
amplicon (200–300 bp). (F) Relative amounts of PCR products from the transcriptionally inactive genomic loci in the CTX of WT control and zQ175 mice.
Data represent mean ± SD; *p<0.001. Five biological replicates each with three technical replicates were used in this assay.
DOI: https://doi.org/10.7554/eLife.42988.021
The following source data and figure supplements are available for figure 6:
Source data 1. Mutant Huntingtin- mediated CBP degradation.
DOI: https://doi.org/10.7554/eLife.42988.026
Figure supplement 1. mHTT expression induces DNA strand breaks in STR but not in CRBL.
DOI: https://doi.org/10.7554/eLife.42988.022
Figure supplement 2. HD patients’ brain and HD transgenic mouse brain accumulate DNA damages.
DOI: https://doi.org/10.7554/eLife.42988.023
Figure supplement 3. HD primary neurons accumulate DNA breaks preferentially in the actively transcribing genome.
DOI: https://doi.org/10.7554/eLife.42988.024
Figure supplement 4. N171-82Q transgenic mouse brain predominantly accumulates strand breaks in the transcriptionally active genome.
DOI: https://doi.org/10.7554/eLife.42988.025
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Figure 7. mHTT facilitates CBP degradation by inactivating ATXN3. (A) Nuclear extracts (NEs) isolated from control primary neurons (Q18 and Q28) and
HD neurons (Q53 and Q109) were analyzed by WBs to measure PNKP, ATXN3, POLR2A, CBP, and CREB levels; HDAC2 was the loading control. (B)
Relative CBP levels in control and HD neurons normalized to HDAC2. Two biological replicates and three technical replicates were used in this assay.
Data represent mean ± SD; *p<0.001. (C) NEs isolated from SH-SY5Y cells expressing control shRNA or ATXN3 shRNA were subjected to WB to
Figure 7 continued on next page
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CBP, we co-expressed Myc-ATXN3 and FLAG-CBP and IP’d Myc-ATXN3 from the NEs. WBs showed
CBP in the Myc-IC (Figure 7G). Conversely, IP of the FLAG-CBP and subsequent WB revealed
ATXN3 (Figure 7H). The PLA results also suggested intracellular interaction between ATXN3 and
CBP (Figure 7I). Confocal microscopy showed distinct colocalization of ATXN3 and CBP in HD and
control brain sections (Figure 7J, arrows). A recent study also showed significantly increased ubiqui-
tination and reduced level of CBP in HdhQ7/Q111 HD transgenic mouse brain (Giralt et al., 2012). To
test whether mHTT expression increases CBP ubiquitination in zQ175 mouse brain, we IP’d CBP
from the NE of zQ175 and control mouse brain. Consistent with a previous report (Jiang et al.,
2003; Giralt et al., 2012), WBs of the CBP IC showed increased CBP ubiquitination in the transgenic
brain (Figure 7K; lower panel). These data suggest that decreased ATXN3 activity due to its interac-
tion with mHTT in the TCR complex may increase ubiquitination, and increased ubiquitination of
CBP may cause aberrant localization of CBP, negatively impacting its solubility in HD. It is also possi-
ble that increased ubiquitination may facilitate degradation of CBP in HD.
Discussion
Our findings reveal a critical proximal event by which polyQ expansions in mHTT induce DNA dam-
age to activate the DDR ATMfip53 pro-apoptotic signaling cascade and disrupt tissue-specific tran-
scriptional activity – key pathogenic features consistently described in HD (Giuliano et al., 2003;
Bae et al., 2005; Illuzzi et al., 2009; Bertoni et al., 2011; Xh et al., 2014). A significant association
of wtHTT with PNKP, ATXN3, POLR2A and associated transcription factors suggest that wtHTT may
act as a scaffold factor to assemble various core components of the TCR complex. Our data suggest
that formation of this functional TCR complex with wtHTT is essential for sensing and editing DNA
lesions in the template strand during transcriptional elongation in post-mitotic differentiated neurons
and may contribute in maintaining genome integrity and neuronal survival. Our results further indi-
cate that interaction of PNKP with wtHTT stimulates its DNA end-processing activity to facilitate neu-
ronal DNA repair. The role of wtHTT in maintaining TCR complex functionality and genome integrity
is further validated by the fact that depletion of endogenous wtHTT protein dramatically depletes
PNKP activity with a concurrent increase in DNA damage accumulation. In contrast, mHTT with
polyQ expansions interacts with several key components of the complex but abrogates the activities
of PNKP and ATXN3, thereby disrupting DNA repair and transcription leading to a possible early
trigger for neurotoxicity and functional decline in HD (Figure 8).
Our data demonstrate that mHTT interaction with PNKP and the resultant decline in PNKP’s enzy-
matic activity was evident in CTX and STR of HD transgenic mouse models but insignificant in the
CRBL. Consistent with these findings, CTX and STR, the most affected brain regions in HD displayed
extensive DNA strand breaks with impaired DNA repair capacity. In contrast, PNKP activity and
genome integrity was marginally affected in CRBL, the brain region that is reported to be relatively
Figure 7 continued
determine ATXN3, HTT, PNKP, CBP, and CREB levels; b-tubulin was used as loading control. (D) Relative CBP levels (normalized to b-actin) in WT
control cells, cells expressing control RNAi or ATXN3 RNAi. Data represent mean ± SD; *p<0.001. (E) NEs isolated from CTX and CRBL of zQ175 and
WT control mice, and analyzed by WB to determine HTT, PNKP, ATXN3, POLR2A and CBP levels; b-tubulin was the loading control. (F) Relative CBP
levels in the CTX and CRBL in WT control and zQ175 mice. CBP levels were normalized to b-tubulin. Data represent mean ± SD; *p<0.001. (G) HEK293
cells were cotransfected with plasmids expressing Myc-ATXN3 and FLAG-CBP, Myc-ATXN3 IP’d with a Myc antibody, analyzed by WB to detect CBP in
the Myc-IC (arrow). (H) HEK293 cells cotransfected with plasmids expressing Myc-ATXN3 and FLAG-CBP, NEs isolated and CBP IP’d with a FLAG
antibody, ICs were subjected to WB to detect ATXN3 (arrow). (I) SH-SY5Y cells were analyzed by PLA to examine interactions between CBP and ATXN3.
Nuclei were stained with DAPI (upper panel). Reconstitution of red fluorescence indicates interaction of CBP with ATXN3 (lower panel). (J) Control
(upper panel) and HD (lower panel) patient brain sections were analyzed by immunostaining with antibodies against ATXN3 (green) and CBP (red) to
assess their in vivo interactions. Merged red and green fluorescence appears as yellow/orange; nuclei stained with DAPI (blue). Arrow indicates the
respective colocalization. (K) Total protein was isolated from control and zQ175 mice CTX, and CBP was IP’d with a CBP antibody (upper panel), and
the IC analyzed with anti-ubiquitin antibody to detect CBP ubiquitination (lower panel).
DOI: https://doi.org/10.7554/eLife.42988.027
The following source data is available for figure 7:
Source data 1. DNA damage precedes neurodegeneration.
DOI: https://doi.org/10.7554/eLife.42988.028
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unaffected in HD. However, no alterations in the steady-state levels of PNKP, ATXN3 and other key
TCR components were observed between CRBL vs. CTX or STR. Our present data do not explain
why mHTT expression specifically impacts PNKP activity and genome integrity in the CTX and STR
but spares CRBL. Further investigation is required to understand region-specific decreases in PNKP
activity and DNA break accumulation in the HD brain. Complete characterization of the TCR com-
plex in different brain regions may provide valuable insight into the selective neuronal vulnerability
to mHTT-mediated toxicity. It will be interesting to understand the mechanism that imparts protec-
tion to CRBL against mHTT and could provide another node in the signaling pathway that could
potentially be developed as a therapeutic target. Furthermore, more rigorous biophysical and struc-
tural studies are necessary with purified peptides/proteins to characterize the true nature of the pro-
tein-protein interactions and interacting partners to understand how this putative HTT-RNA
polymerase complex maintains neuronal genome integrity and survival.
Figure 8. Proposed mechanism by which mHTT triggers neurotoxicity in HD. Schematic diagram of our hypothesized mechanism by which polyQ
expansions in mHTT compromise the functional integrity of the TCR complex. Normal HTT forms a multiprotein TCR complex with POLR2A, ATXN3,
PNKP, CBP, and additional DNA repair enzymes, and this structure monitors and edits DNA strand breaks/damage during transcriptional elongation,
preserving genome integrity, transcription and neuronal survival. In HD, polyQ expansions in mHTT impair the normal function of the TCR complex;
mHTT-mediated inactivation of PNKP activity impairs DNA repair, which leads to the persistence of DNA strand breaks and chronic activation of ATM-
p53 pro-apoptotic signaling. Additionally, mHTT-mediated inactivation of ATXN3’s deubiquitinating activity facilitates ubiquitination and degradation
of CBP, impairing CBP-CREB-regulated gene transcription and further amplifying pro-degenerative output in the HD brain. PolyQ expansion in mHTT
thus adversely impacts DNA repair and transcription and neural function and survival, triggering neurotoxicity and functional decline in HD.
DOI: https://doi.org/10.7554/eLife.42988.029
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It is notable that the HTT-TCR complex preferentially associates only with the transcriptionally
active genome both in vitro and in vivo. This suggests that the complex could be actively involved in
repairing lesions in the template DNA strand during transcription and thus maintaining sequence
integrity of the transcriptionally active genomes over the non-transcribing genome. This HTT-TCR
complex may provide an additional layer of protective mechanism to maintain the sequence integrity
of highly transcriptionally active genes in post-mitotic neurons. Depletion of PNKP activity by mHTT
and subsequent accumulation of DNA strand breaks in the transcriptionally active genome extends
our previous report (Chakraborty et al., 2016). Collectively, these data support our hypothesis that
polyQ expansions in HTT result in the preferential accumulation of strand breaks in the transcription-
ally active genome. Persistent DNA strand breaks in the actively transcribing genes may stall or
impair transcription elongation, preventing adequate expression of a wide variety of neuronal genes
and may contribute to the complexity and variability of HD pathology. Moreover, unrepaired lesions
may further induce chronic activation of ATMfip53 signaling, as evidenced by increased phosphory-
lation of ATM, H2AX, and p53 in the HD brain (Figure 5—figure supplement 1). Chronic ATM-p53
pathway activation resulted in an increased expression of several of the p53 target genes may facili-
tate neuronal apoptosis in HD. These data support the hypothesis that decreased PNKP activity
could be an important proximal event that triggers early neurotoxicity in HD; however, it remains to
be tested whether restoration of PNKP activity and DNA repair efficiency can rescue genome integ-
rity and structural and behavioral defects in HD models.
Our results provide evidence that ATXN3 is another key regulatory component of the TCR com-
plex. Our data suggest that the mHTT-mediated decrease in ATXN3 activity either enhances degra-
dation of specific TCR complex components or prevents appropriate formation of the TCR complex
in HD. We propose that abrogating ATXN3 activity is a potential mechanism by which mHTT
decreases CBP activity and thus adversely impacts the transcription of CREB-dependent genes in
HD. ATXN3 binds and deubiquitinates both mono- and polyubiquitin chains in target proteins
(Burnett et al., 2003; Chai et al., 2004). ATXN3 inactivation in mice increases protein ubiquitination
(Schmitt et al., 2007), so diminished ATXN3 activity could influence CREB-regulated gene expres-
sion as described in HD (Wyttenbach et al., 2001). Since disruption of CREB activity in the brain
triggers neurodegeneration (Mantamadiotis et al., 2002), mHTT-mediated decreases in ATXN3,
CBP, and CREB activities might compromise neuronal function and trigger neurotoxicity, further
amplifying pro-degenerative output in HD. The identification of HTT, CBP, PNKP, and ATXN3 as key
regulatory components of the TCR complex and our description of how polyQ expansions disrupt
the complex’s functional integrity provide important insight into how mHTT could coordinately dis-
rupt CREB-mediated transcription, increases DNA strand breaks, and activates ATMfip53 signaling.
Collectively, these events compromise neuronal survival in HD. We hypothesize that POLR2A-medi-
ated transcription might temporarily pause at DNA lesions, leading to mono-ubiquitination of spe-
cific TCR complex components, which signals complex assembly to stimulate and/or coordinate
lesion repair in normal cells. ATXN3 deubiquitinates the components after repair, and normal tran-
scription resumes. In contrast, the TCR complex stalls at strand breaks in mHTT-carrying cells, and
due to reduced ATXN3 activity, specific complex component (s) are polyubiquitinated and accumu-
late aberrantly in polyQ inclusions (Figure 8). We propose that mHTT-mediated ATXN3 inactivation
might impair CBP/CREB-dependent transcription, while reduced PNKP activity might result in DNA
break accumulation and DDR pathway activation. The combination of chronic DDR signaling and
dysregulation of CREB-dependent genes could trigger selective neuronal degeneration, a hallmark
of HD. Defective DNA repair in post-mitotic neurons is an emerging causative factor of cognitive
decline in neurodegenerative diseases (Madabhushi et al., 2014; Madabhushi et al., 2015;
Rass et al., 2007). Consistent with our findings, point mutations in PNKP result in microcephaly and
seizures (Shen et al., 2010), whereas a frame-shift mutation in the PNKP gene was identified in a
neurodegenerative disorder characterized by epilepsy (Poulton et al., 2013). Therefore, mHTT-
mediated ablation of PNKP activity could lead to impaired DNA repair, persistent accumulation of
DNA strand breaks that may in part contribute to neurotoxicity and neuronal dysfunction in HD.
This study provides multiple lines of evidence suggesting that mHTT-mediated loss of DNA repair
and deubiquitinating activity could possibly be critical proximal events that impair the TCR. This
could provide a mechanistic link between transcriptional dysregulation leading to aberrant activation
of ATM-dependent pro-degenerative pathways and early neurotoxicity in HD. Although the final bio-
logical output triggered by impaired TCR and unrepaired DNA strand breaks in HD remains to be
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fully described, the present data indicate a potential mechanism by which polyQ expansions in
mHTT could disrupt the functional integrity of TCR complex and compromises transcriptional regula-
tion and genomic integrity in post-mitotic neurons. Molecular strategies that interfere with the inter-
action of mHTT with the TCR complex could reduce neurotoxicity and slow functional decline in HD.
Alternatively, molecular approaches to stimulate PNKP activity could be a reasonable way to combat
transcriptional dysregulation and inappropriate activation of pro-apoptotic signaling in HD. Our find-
ings could help elucidate the cell type-specific pattern of pathology in HD. We propose the possibil-
ity that the compromised TCR efficiency in the basal ganglia or cortex could render these neuronal
populations more vulnerable. Collectively, our findings suggest an intriguing molecular mechanism
that could explain how mHTT expression in HD could compromise genome integrity and neuronal
survival.
Materials and methods
Plasmid construction
The construction of plasmids expressing the N-terminal fragment of HTT (exon1: NT-HTT-Q23 and
NT-HTT-Q148) and full-length HTT (FL-HTT-Q23 and FL-HTT-Q148) was described previously
(Tanaka et al., 2006). The N-terminal fragments of wtHTT and mHTT were sub-cloned in pAcGFPC1
(Clontech, USA) to construct pGFP-NT-HTT-Q23 and pGFP-NT-HTT-Q97, respectively. The number
of CAG repeats contracted to 97 after propagation in Escherichia coli. The plasmids pGFP-NT-HTT-
Q23 and pGFP-NT-HTT-Q97 were digested with NheI and MluI, and the fragments containing GFP-
NT-HTT-Q23 and GFP-NT-HTT-Q97 were sub-cloned into the TET-inducible responder plasmid
pTRE3G (Clontech, USA) using appropriate linkers. The plasmid pTet-ON (Clontech, USA) and
responder plasmids (pTRE-GFP-NT-HTT-Q97 or pTRE-GFP-NT-HTT-Q23) were transfected into SH-
SY5Y cells, and clones were selected with neomycin. The stable inducible clones expressing GFP-
NT-HTT-Q97 or GFP-NT-HTT-Q23 were incubated with medium containing doxycycline (500 ng/mL),
and transgene expression was assessed by WB using anti-GFP antibodies. The PNKP cDNA was
cloned into pcDNA3.1/hygro (Invitrogen, USA) to construct pRPS-PNKP, which was transfected into
SH-SY5Y cells encoding inducible GFP-NT-HTT-Q23 and GFP-NT-HTT-Q97. The clones were
selected for hygromycin resistance. PNKP expression was examined by WB, and PNKP activity was
assessed as described previously (Chatterjee et al., 2015). To express PNKP and its functional
domains as FLAG-tagged peptides, the full-length cDNA and FHA domain (1–300 amino acids),
kinase domain (131–337 amino acids), phosphatase domain (338–521 amino acids), FHA and kinase
domain (1–337 amino acids), and kinase and phosphatase domain (131–521 amino acids) were PCR-
amplified using specific primers and cloned into plasmid pCMV-DYKDDDDK (Clontech, USA).
Plasmids for the bimolecular fluorescence complementation assay
Plasmids pBiFC-VN173 (encoding 1 to 172 N-terminal amino acids of cyan fluorescent protein, CFP)
and pBIFC-VC155 (encoding 155 to 238 C-terminal amino acids of CFP) were kindly provided by Dr.
Chang-Deng Hu (Addgene plasmids 22011 and 22010). The N-terminal fragments of HTT cDNA
(encoding 23 or 97 glutamines) were cloned in-frame with the C-terminal amino acids of CFP in plas-
mid pBiFC-VC155 to construct pVC-NT-HTT-Q23 and pVC-NT-HTT-Q97, respectively. Full-length
PNKP or its catalytic domain (phosphatase and kinase domains, 131–521 amino acids) was cloned in
plasmid pBIFC-VN173 to construct pVN-PNKP or pVN-(PHOS + KIN)-PNKP, respectively. SH-SY5Y
cells (2  105 cells) were grown on chamber slides and transfected 24 hr later. Plasmids pVN-
(PHOS + KIN)-PNKP and pVC-HTT-Q23 or pVN-(PHOS + KIN)-PNKP and pVC-HTT-Q97 were
cotransfected, and reconstitution of the green/yellow fluorescence of CFP was monitored by fluores-
cence microscopy.
Cell culture and plasmid transfection
Human neuroblastoma SH-SY5Y cells were purchased from ATCC (Cat # CRL-2266) and cultured in
Dulbecco’s minimum essential medium (DMEM) containing 15% fetal bovine serum (FBS), and 1%
B-27 (Invitrogen, USA). SH-SY5Y cells stably encoding inducible GFP-NT-HTT-Q23 or GFP-NT-HTT-
Q97 were cultured in DMEM, and transgene expression was induced by adding doxycycline to the
medium to a final concentration of 500 ng/mL. PC12 cells carrying full-length wtHTT-Q23 or mHTT-
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Q148 were cultured in DMEM containing 15% FBS and doxycycline (500 ng/mL). HTT expression
was induced by withdrawing doxycycline from the media for 5–7 days, and transgene expression
was verified by WB. Plasmids expressing the RNAi targeting ATXN3 were from Dharmacon, USA.
SH-SY5Y cells were transfected with the ATXN3-RNAi plasmids using Lipofectamine RNAi-MAX
reagent (Invitrogen, USA); stable cells were selected for puromycin resistance and differentiated in
DMEM containing 5 mM retinoic acid. All the cell lines were authenticated by short tandem repeat
analysis in the UTMB Molecular Genomics Core. The possible mycoplasma contaminations in all the
cell lines were tested using GeM Mycoplasma Detection Kit (SIGMA, Cat# MP0025) using a PCR
based screening method and cells were found to be free from mycoplasma contamination.
Analysis of HTT-associated TCR proteins by co-immunoprecipitation
(Co-IP)
Co-IP from NEs: NEs from SH-SY5Y cells were isolated and treated with benzonase to remove DNA
and RNA to avoid nucleic acid-mediated Co-IP. Specific target proteins were IP’d, and the IC was
washed extensively with cold Tris-buffered saline (50 mM Tris-HCl [pH 7.5] 200 mM NaCl) containing
1 mM EDTA, 1% Triton-X100, and 10% glycerol. The complexes were eluted from the beads with 25
mM Tris-HCl (pH 7.5) and 500 mM NaCl and analyzed by WB.
Co-IP from tissue: Approximately 250 mg of cortex from freshly sacrificed WT mice was harvested
and homogenized with 4 volumes of ice-cold buffer (0.25 M sucrose, 15 mM Tris-HCl [pH 7.9], 60
mM KCl, 15 mM NaCl, 5 mM EDTA, 1 mM EGTA, 0.15 mM spermine, 0.5 mM spermidine, 1 mM
dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride [PMSF], and protease inhibitors [Roche Applied
Science, Germany]) with ~20 strokes to disrupt tissues (Chakraborty et al., 2015). Homogenization
was continued until a single-cell slurry was obtained, incubated on ice for 15 min, and centrifuged at
1,000  g to obtain the cell pellet. NEs were then prepared from the cell pellet for co-IP analysis.
The ICs were analyzed by WB to identify interacting protein partners.
HD autopsy brain tissue samples
Human autopsy specimens were obtained in accordance with local legislation and ethical rules. Con-
trol brain samples were collected from age-matched individuals without neurodegenerative disor-
ders. The HD brain tissue samples were obtained from patients with HD who were clinically
characterized based on the presence of chorea and motor, mood, and cognitive impairment. The
molecular diagnosis of HD was established by analyzing genomic DNA extracted from peripheral
blood using a combination of PCR and Southern blotting. HTT CAG repeat lengths were established
by sequencing the expansion loci of the mutant allele. All brain autopsies were immediately frozen
in liquid nitrogen and stored at  80˚C until further analysis.
HD iPSC differentiation
Products purchased from Thermo Fisher Scientific (Waltham, MA USA), unless otherwise specified.
Three control: CS25iCTR18n6, CS14iCTR28n6, CS83iCTR33n1 and three HD: CS87iHD50n7,
CS03iHD53n3 and CS09iHD109n1 iPSC lines were derived and cultured as previously described on
hESC-qualified Matrigel (HD iPSC HD iPSC Consortium, 2017). Once at 70% confluency, neural
induction and further differentiation of neural progenitors with the addition of Activin A (Peprotech,
USA), was performed as previously described in Telezhkin et al. (2016). Neuronal maturation was
performed as previously described (Telezhkin et al., 2016) on Nunc six well plates. After 3 weeks of
maturation, medium was removed and cells were washed once with PBS pH 7.4, without Mg2+ and
Ca2+. Subsequently, cells were washed with 4˚C PBS pH 7.4, without Mg2+ and Ca2+, and scraped
using a cell scraper, pipetted into a centrifuge tube and centrifuged at 250 x g for 3 min. PBS was
removed and samples were flash frozen in liquid nitrogen.
HD transgenic mice
The HD knock-in mouse model zQ175 expresses full-length mHTT from the endogenous mouse Htt
promoter (Menalled et al., 2012). The N171-82Q transgenic mouse line expresses the truncated
N-terminus of human HTT cDNA with a polyQ repeat length of 82 under control of the mouse prion
promoter (Schilling et al., 1999). Heterozygous transgenic mice and control non-transgenic litter-
mates (n = 4–5 pools of two animals per genotype) were sacrificed, and fresh brain tissues were
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used for enzyme assays, isolating genomic DNA, and obtaining protein for WB analyses. For immu-
nofluorescence assays, transgenic and control littermate mice were deeply anesthetized and trans-
cardially perfused with sterile phosphate-buffered saline (PBS) followed by 4% paraformaldehyde in
PBS. Brains were post-fixed overnight in fixative solution and embedded in OCT and stored in liquid
nitrogen. Slides with 4-mm-thick frozen sections were processed for immunostaining with appropriate
antibodies. All procedures involving animals were in accordance with the National Institutes of
Health Guide for the care and use of Laboratory Animals, and approved by the Institutional Animal
Care and Use Committee of University of California Irivine (protocol #: AUP-18–155); and Duke Uni-
versity (protocol #: A225-17-09).
Alkaline comet assays
Alkaline comet assays were performed using a Comet Assay Kit (Trevigen, USA). Cells were sus-
pended in 85 mL ice-cold PBS and gently mixed with an equal volume of 1% low-melting-point aga-
rose. The cell suspension was dropped onto an agarose layer and incubated in lysis buffer for 1 hr.
After lysis, slides were incubated in buffer containing 0.3 M NaOH, 1 mM EDTA (pH 13) for 40 min
and electrophoresed for 1 hr. After neutralization, slides were stained and analyzed with a fluores-
cence microscope.
Antibodies and WB analysis
Cell pellets or brain tissues were homogenized, and total protein was isolated using a protein extrac-
tion kit (Millipore, USA). The cytosolic and nuclear fractions were isolated from cells/tissue using a
NE-PER protein extraction kit (Thermo Scientific, USA). WBs were performed according to the stan-
dard procedure, and each experiment was performed at least three times to ensure statistically sig-
nificant results. The antibodies for p53 (Cat #9282), p53-S15 (Cat #9286), p53-S20 (Cat #9287), p53-
S46 (Cat #2521), Chk2 (Cat #2662), Chk2-T68 (Cat #2661), CBP (Cat #7389) and APE1 (Cat #4128)
were from Cell Signaling, USA; anti-H2AX (Cat #ab11175) and gH2AX-S139 (Cat #ab11174) were
from Abcam, UK; anti-ATM (Cat #1549–1) and ATM-S1981 (Cat #2152–1) were from Epitomics, USA,
or anti-ATM from Santa Cruz (sc-23921), anti-ataxin-3 monoclonal antibody (Cat #MAB 5360), mono-
clonal anti-HTT antibody (MAB 2170) and 5TF1-1C2 (Mab1574) were from Millipore, USA. Rabbit
polyclonal HAP-1 (Cat #TA306425) was from Origene, USA, and mouse monoclonal HAP-1 (MA1-
46412) was from Thermo Scientific, USA. RNA pol II (sc-899) and DNA ligase 3 (sc-135883) were
from Santa Cruz Biotechnology, USA. PNKP rabbit polyclonal antibody (Cat #MBP-1-A7257) was
from Novus Biologicals, USA, and BioBharati Life Science (Cat# BB-AB0105), India, and PNKP mouse
monoclonal antibody was a kind gift from Dr. Michael Weinfeld (University of Alberta, Canada).
Immunohistochemical analysis
SH-SY5Y cells or frozen brain sections were immunostained with anti-PNKP, HTT, CBP, POLR2A,
ATXN3, and anti-polyQ 5T1-1C2 antibodies. Nuclei were stained with DAPI (Molecular Probe, USA)
and imaged under a confocal microscope.
Cell toxicity assay
Expression of mHTT or wtHTT was induced in PC12 cells by removing doxycycline from the culture
medium for 4–7 days. Induced cells were dissociated with Accutase (Gibco), and collected by centri-
fugation. Cell toxicity was assayed using a commercially available Annexin-V Cell Toxicity Assay kit
(4830–01 K, Trevigen, USA). 1  106 Cells were incubated at room temperature with 1 ml Annexin-V-
FITC (1 mg/ml) and 5 ul Propidium Iodide, in the provided binding buffer, for 15 min, before diluting
with binding buffer. FITC fluorescence was analyzed by flow cytometry using a Cytoflex (Beckman
Coulter), measuring 10,000 events per sample. Gating on main cell population was performed by
FSC/SSC gating. Positive thresholds determined with unstained negative control, and H2O2 treated
positive control samples. Identical thresholds applied to all samples. Data were analyzed using
CytExpert software (Beckman Coulter).
Image collection
Images were collected using a Zeiss LSM-510 META confocal microscope with 40  or 60  1.2
numerical aperture water immersion objectives. Images were obtained using two excitation
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wavelengths (488 and 543 nm) by sequential acquisition. Images were collected using 4-frame-Kall-
man-averaging with a pixel time of 1.26 ms, a pixel size of 110 nm, and optical slices of 1.0 mm.
Z-stack acquisition was performed at 0.8 mm steps. Orthogonal views were processed with LSM 510
software.
Caspase-3 activity measurements
Caspase-3 activities were measured using a Caspase-3 assay kit (BD Biosciences, USA) based on
hydrolysis of the substrate acetyl-Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA), resulting in release
of the p-nitroaniline (pNA) moiety. Released pNA is detected at 405 nm. Comparison of pNA absor-
bances from the sample and control allows determination of the fold increase in caspase-3 activity
(relative caspase-3 activity is expressed in arbitrary units).
In situ proximity ligation assay (PLA)
SH-SY5Y cells were plated on chamber slides and cultured in DMEM for 24 hr. SH-SY5Y cells or brain
sections were fixed with 4% paraformaldehyde, permeabilized with 0.2% Tween-20, washed with
1  PBS, incubated with primary antibodies for PNKP (mouse monoclonal), HTT (rabbit polyclonal
and mouse monoclonal), PNKP (mouse monoclonal), POLR2A (rabbit polyclonal), HAP-1 (rabbit poly-
clonal and mouse monoclonal), ATXN3 (rabbit polyclonal and mouse monoclonal), and DNA ligase 3
(rabbit polyclonal). These samples were subjected to PLAs using the Duolink PLA kit (O-Link Bio-
sciences, Sweden). Nuclei were stained with DAPI, and PLA signals were visualized under a fluores-
cence microscope at 20  magnification.
PNKP activity measurements
The 3’-phosphatase activity of PNKP in the nuclear extract (250–500 ng) of cells/mouse brains or
with purified recombinant His-tagged PNKP (25 fmol) was conducted as we described previously
(Wiederhold et al., 2004; Mandal et al., 2012; Chatterjee et al., 2015). Nuclear extracts for the 3’
phosphatase assay was prepared following standard protocols from cells (Chakraborty et al., 2016)
or mouse brains tissues (Chakraborty et al., 2015). A 32P-labeled 3’-phosphate-containing 51-mer
oligo substrate with a strand break in the middle (5 pmol) was incubated at 37˚C for 15 min in buffer
A (25 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1 mM DTT, 10% glycerol and 0.1 mg/ml
acetylated BSA) with 5 pmol of unlabeled (cold) substrate. The reaction was stopped by adding
buffer B (80% formamide, 10 mM NaOH) and the reaction products were electrophoresed on a 20%
Urea-PAGE to measure the amount of 3’ phosphate release from the radio-labeled substrate. The
radioactive bands were visualized in PhosphorImager (GE Healthcare, USA). The data were repre-
sented as % of the phosphate release (% product) with the total radiolabeled substrate as 100.
Total DNA repair assay
Total DNA repair assays were carried out according to the protocol of Wiederhold et al. (2004).
Briefly, 10 pmol DNA substrate (a 51-mer DNA-oligo) annealed to two shorter DNA duplexes, one
containing 3’-P and the other with 5’-P with a 4-nt gap in the middle was used to assess total repair
activity (DNA end cleaning +gap filling through polymerization +ligation to fill the ends) in NEs (2.5
mg) from wtHTT- and mHTT-expressing neuronal cells and zQ175 and control mouse brain samples.
Total repair activity was also assessed with the same substrate with DNA oligos containing 3’-OH
(clean DNA ends). In both cases, the 20 mL reaction mixture contained 1 mM ATP, 50 mM unlabeled
dNTPs, and 0.5 pmol [a 32P]-dCTP (the concentration of cold dCTP was lowered to 5 mM) in BER
buffer and incubated for 45 min at 30˚C. The reaction products were analyzed with 20% urea-poly-
acrylamide gel electrophoresis, and the radioactive bands were detected in a Phosphorimager (GE
Life Sciences, USA).
Gene expression analysis by real-time quantitative RT-PCR
Freshly dissected brain tissue from transgenic and age-matched control mice was homogenized in
TRIzol (Thermo Scientific, USA), and total RNA was extracted using an RNA extraction kit (Qiagen,
USA) and purified using a DNA-free DNAse Kit (Ambion, USA). Next, 1 mg of total RNA was reverse-
transcribed using an RT-PCR kit (Clontech, USA). A cDNA aliquot from each reaction was quantified,
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and 500 ng of cDNA from each reaction was used for qRT-PCR. 18S rRNA was used as control for
the qRT-PCR analysis. The reactions were repeated three times using the following primers.
Neurod1: F: AGCCCTGATCTGGTCTCCTT; R: CTGGTGCAGTCAGTTAGGGG
Neurod2: F: AAGCCAGTGTCTCTTCGTGG; R: TTGGACAGCTTCTGCGTCTT
Neurog1: F: CCAGGACGAAGAGCAGGAAC; R: GGTCAGAGAGTGGTGATGCC
Tubb3: F: TGAGGCCTCCTCTCACAAGT; R: ACCACGCTGAAGGTGTTCAT
Eno2 g: F: CCCAGGATGGGGATTTTGCT; R: CCTCCCCTGATCTGCTACCT
Pol b: F: TTCCACCGGTAAGACCCAGG; R: GCCAGTAACTCGAGTCAGGA
Myod1: F: AGCATAGTGGAGCGCATCTC; R: TTGGGGCTGGATCTAGGACA
Myog: F: GAGGAAGTCTGTGTCGGTGG; R: CCACGATGGACGTAAGGGAG
Myh2: F: CGAGAGACGAGTGAAGGAGC; R: GAATCACACAGGCGCATGAC
Myh4: F: AGCGCAGAGTGAAGGAACTC; R: TCTCCTGTCACCTCTCAACAGA
Myh6: F: ATAAAGGGGCTGGAGCACTG; R: TCGAACTTGGGTGGGTTCTG
Myh7: F: CCTTACTTGCTACCCTCAGGTG; R: GGCCATGTCCTCGATCTTGT
Gapdh F: ATGAGAGAGGCCCAGCTACT; R: TTTGCCGTGAGTGGAGTCAT
Bcl2L11: F: TTGGATTCACACCACCTCCG; R: CGGGATTACCTTGCGGTTCT
Pmaip 1: F: CTCGCTTGCTTTTGGTTCCC; R: ACGACTGCCCCCATACAATG
Bid: F: CCACAACATTGCCAGACATCTCG: R: TCACCTCATCAAGGGCTTTGGC
Pidd: F: ACAGAAGAGCCTCGGCAAGTCT: R: GAAAGGCACAGCAGAGGGCTTA
Apaf1: F: CACGAGTTCGTGGCATATAGGC: R: GGAAATGGCTGTCGTCCAAGGA
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed using fresh brain tissue of WT mice as previously described
(Chakraborty et al., 2016; Sailaja et al., 2012). Briefly, 80–100 mg of freshly harvested CTX was
chopped into small pieces and fixed in 1% formaldehyde for 15 min. The samples were centrifuged
at 440  g for 5 min at room temperature, and 0.125 M glycine was added to terminate cross-link-
ing. The samples were washed two to three times with ice-cold PBS (containing protease inhibitors)
and centrifuged each time at 440  g for 4 min at 4˚C. The pellet was resuspended in 1 mL ice-cold
lysis buffer (10 mM EDTA, 1% [w/v] SDS, 50 mM Tris-HCl [pH 7.5]) with protease inhibitors and
PMSF for 15 min and homogenized to produce a single-cell suspension. The samples were then
transferred to pre-cooled 1.5 mL tubes and centrifuged at 2260  g for 5 min. The pellet was resus-
pended in lysis buffer and sonicated to generate ~500 bp DNA fragments. The samples were centri-
fuged at 20,780  g for 30 min at 4˚C, and supernatants were collected for ChIP. The sheared
chromatin was IP’d for 6 hr at 4˚C with 10 mg isotype control IgG (Santa Cruz Biotechnology, USA:
sc-2027) or anti-HTT antibody. After DNA recovery with proteinase K treatment followed by phenol
extraction and ethanol precipitation, 1% of input chromatin and the precipitated DNA were analyzed
by qPCR with the following primers. ChIP data are presented as percent binding relative to the input
value.
Neurod1:
F: CTGCAAAGGTTTGTCCCAAGC; R: CTGGTGCAGTCAGTTAGGGG
Neurod2:
F: CAGGCCCTCCCAAGAGACTT; R: TCGTGTTAGGGTGAAGGCGT
Neurog1:
F: GCTTGCTCCAGGAAGAACCT; R: AGAGACACCGCTACTAGGCA
Tubb3:
F: GTGGGGCTCTCCCCTAAAAC; R: TTGGGAGCGCACAGTTAGAG
Eno2 g:
F: TAGGGGTGCCTAGTCCTGTC; R: GAGTGCTGGATGTGTGGTCA
Myod1:
F: ATCTGACACTGGAGTCGCTTT; R: TTAGTCTCAGCTGCTGGTTCC
Myog:
F: GGCCACCAGAGCTAGAACAG; R: ATGAAGGCTGTGGACTTGGG
Myh2:
F: TCAGTGAGCAGTGGGAGCTA; R: GTACAAACACGGGGACACCC
Myh4:
F: AGGTGTACAACTCCGTGGGT; R: GCTCTAGCAAGACCAGTCACG
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Myh6:
F: TCGTGCCTGATGACAAGGAG; R: CTTTCTGGCAAGCGAGCATC
Myh7:
F: ATTGGTGCCAAGGTGGGTTT; R: CCTGGGGTTCCCAGAATCAC
LA-qPCR analysis to assess DNA strand breaks
LA-qPCR assays were carried out following an existing protocol (Santos et al., 2006). Briefly, tissues
were harvested from the cortex (CTX), striatum (STR), and cerebellum (CRBL) of control and HD
transgenic mice, and genomic DNA was extracted using the genomic-tip 20/G kit (Qiagen, Ger-
many). Genomic DNA was quantified, and gene-specific LA-qPCR analyses were performed using
Long Amp Taq DNA polymerase (NEB, USA). Various genomic loci were PCR-amplified from actively
transcribing genes in brain (e.g., neuronal differentiation factor 1 and 2 [Neurod1 and Neurod2],
neurogenic basic-helix-loop-helix protein neurogenin 1 [Neurog1], tubulin beta three class III
[Tubb3], neuron-specific enolase 2 [Eno2g ], and DNA polymerase b [Pol b]). Non-transcribing loci (e.
g., myogenic differentiation factor 1 [Myod1]; myogenic factor 4; myogenin [Myog]; and myosin
heavy chain 2, 4, 6, or 7 [Myh2, Myh4, Myh6, or Myh7]) were amplified using the primers listed
below. Loci from genomic DNA isolated from iPSC-derived control and HD primary neurons were
PCR-amplified with the primers listed below. The cycle numbers and DNA concentrations were stan-
dardized before each final reaction so that the reaction remained within the linear amplification
range (Santos et al., 2006). The final PCR conditions were optimized at 94˚C for 30 s (94˚C for 30 s,
55–60˚C for 30 s depending on the oligo annealing temperature, 65˚C for 10 min) for 25 cycles and
65˚C for 10 min. Each reaction used 15 ng of DNA template, and the LA-qPCRs for all studied genes
used the same stock of diluted DNA samples to avoid amplification variations due to sample prepa-
ration. A small DNA fragment for each gene was amplified to normalize large fragment amplifica-
tion. The PCR conditions were 94˚C for 30 s, 54˚C for 20 s, 68˚C for 30 s for 25 cycles, and 68˚C for 5
min. Short PCR used 15 ng of the template from the same DNA aliquot. The amplified products
were visualized on gels and quantified with the ImageJ software based on three independent repli-
cate PCRs. The extent of damage was calculated according to our previously described method
(Chakraborty et al., 2016).
Mouse neurod1
Long: F: CTCGCAGGTGCAATATGAATC; R: GCAACTGCATGGGAGTTTTCT
Short: F: CTGCAAAGGTTTGTCCCAAGC; R: CTGGTGCAGTCAGTTAGGGG
Mouse neurod2
Long: F: GGCAGTGGTTGGGATGGTAT; R: CTCACTCTGTGCTGTCTGTCTC
Short: FP: CAGGCCCTCCCAAGAGACTT; R: TCGTGTTAGGGTGAAGGCGT
Mouse neurog1
Long: F: GATGAGCCCCTGAAGACGAG; R: GCCAATCTTGCTTCTTGCGT
Short: F: GCTTGCTCCAGGAAGAACCT; R: AGAGACACCGCTACTAGGCA
Mouse tubb3
Long: F: GGTACAGGGGATGTGGTTGG; R: GAGTCTCCTGCCTGTCCCTA
Short: F: GTGGGGCTCTCCCCTAAAAC; R: TTGGGAGCGCACAGTTAGAG
Mouse eno2 g
Long: F: CTTGTTCTTCGGGGACCCTC; R: CATCCGTGTGCTTAAGGGGT
Short: F: TAGGGGTGCCTAGTCCTGTC; R: GAGTGCTGGATGTGTGGTCA
Mouse pol B
Long: F: TATCTCTCTTCCTCTTCACTT; R: GTGATGCCGCCGTTGAGGGTCTCCTG
Short: F: TATGGACCCCCATGAGGAACA; R: AACCGTCGGCTAAAGACGTG
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Mouse myod1
Long: F: ATAGACTTGACAGGCCCCGA; R: GGACCGTTTCACCTGCATTG
Short: F: ATCTGACACTGGAGTCGCTTT; R: TTAGTCTCAGCTGCTGGTTCC
Mouse myog
Long: F: ACAAGCCTTTTCCGACCTGA; R: CCATGGCCAAGGCGACTTAT
Short: F: GGCCACCAGAGCTAGAACAG; R: ATGAAGGCTGTGGACTTGGG
Mouse myh2
Long: F: ATCTCAGGAGCACCCATCCT; R: GAAAAGGGTGTGCCAAGCAG
Short: F: TCAGTGAGCAGTGGGAGCTA; R: GTACAAACACGGGGACACCC
Mouse myh4
Long: F: GACGTGGAACTGTTAGGCCA; R: AAGCCAGAGTCTTCAACCCG
Short: F: AGGTGTACAACTCCGTGGGT; R: GCTCTAGCAAGACCAGTCACG
Mouse myh6
Long: F: GACAAGGGGCATTGTAGCCT; R: TCTGCCTACCTTATGGGGCT
Short: F: TCGTGCCTGATGACAAGGAG; R: CTTTCTGGCAAGCGAGCATC
Mouse myh7
Long: F: TTTGGGTTGGCCTGTCAGTT; R: ATCCCTAGCTGGGGCTTGTA
Short: F: ATTGGTGCCAAGGTGGGTTT; R: CCTGGGGTTCCCAGAATCAC
Human TUBB3
Long: F: TGCTTCTCATGCTTGCTACCAC; R: TCTGTCCCTGTAGGAGGATGT
Short: F: CCTGTCCCTTTGTTGGAGGG; R: CGAGGTGGGCTAACAATGGA
Human NEUROD1
Long: F: CCGCGCTTAGCATCACTAAC; R: TGGCACTGGTTCTGTGGTATT
Short: F: TGCCTCTCCCTTGTTGAATGTAG; R: TTCTTTTTGGGGCCGCGTCT
Human POLB
Long: F: CATGTCACCACTGGACTCTGCAC R: CCTGGAGTAGGAACAAAAATTGCT
Short: F: AGTGGGCTGGATGTAACCTG R: CCAGTAGATGTGCTGCCAGA
Human ENO2 g
Long: F: ACGTGTGCTGCAAGCAATTT; R: CCTGAAACTCCCCTGACACC
Short: F: GGTGAGCAATAAGCCAGCCT; R: CAGCTTGTTGCCAGCATGAG
Statistical analysis
Data reported as mean ± SD and the statistical analysis was performed using Sigma Plot (SYSTAT
Software). Differences between two experimental groups were analyzed by Student’s t test (2-tail,
assuming unequal variances). When comparing multiple groups, One-way ANOVA was performed
followed by Tukey’s post-hoc test to determine significance. In all cases, p<0.05 was considered
significant.
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